The US Panel on Review of Blood and Blood Derivatives stated that when it came to prophylactic use of AHF in people with congenital Factor 8 deficiency, its safety had not been well evaluated - "the risks may outweigh the benefits" and "a similar situation applies to recommendations for home therapy either in chronic low dose prophylactic use or for intermittent, episodic home therapy. Antihemophilic Factor (Human) usage is limited because of risk of transmitting viral hepatitis."